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Abstract: Curcumin has been used as a traditional medicine and/or functional food in several cultures
because of its health benefits including anticancer properties. However, poor oral bioavailability of
curcumin has limited its oral usage as a food supplement and medical food. Here we formulated
curcumin pellets using a solid dispersion technique. The pellets had the advantages of reduced
particle size, improved water solubility, and particle porosity. This pellet form led to an improvement
in curcumin’s oral bioavailability. Additionally, we used the C-Map and Library of Integrated
Network-Based Cellular Signatures (LINCS) Unified Environment (CLUE) gene expression database
to determine the potential biological functions of formulated curcumin. The results indicated that,
similar to conventional curcumin, the formulated curcumin acted as an NF-κB pathway inhibitor.
Moreover, ConsensusPathDB database analysis was used to predict possible targets and it revealed
that both forms of curcumin exhibit similar biological functions, including apoptosis. Biochemical
characterization revealed that both the forms indeed induced apoptosis of hepatocellular carcinoma
(HCC) cell lines. We concluded that the formulated curcumin increases the oral bioavailability in
animals, and, as expected, retains characteristics similar to conventional curcumin at the cellular level.
Our screening platform using big data not only confirms that both the forms of curcumin have similar
mechanisms but also predicts the novel mechanism of the formulated curcumin.
Keywords: curcumin; formulated curcumin; pharmacokinetics; aurora kinase A; hepatocellular
carcinoma
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1. Introduction
The use of nutraceutical or functional and medical foods as alternative medicine, in addition to
supplementary foods, has been on the rise in recent years [1,2]. The delivery of active ingredients is
important in order to obtain beneficial effects for the human body.
Curcumin has been used for many years as a naturally occurring alternative medicine and
functional food for the treatment of many diseases. Curcumin is a polyphenol extracted from the
rhizome of Curcuma longa L., which has phenolic groups and conjugated double bonds [3]. It has strong
anti-oxidant, anti-inflammatory, anti-septic, anti-proliferative, and wound-healing properties [4–8].
In addition, curcumin can reverse multidrug resistance of cancer cells, suggesting that it can also serve
as a supplement to traditional chemotherapy [9,10]. Several lines of evidence show that curcumin
exerts potent anticancer effects against a broad range of human cancer cells, including prostate, colon,
breast, ovarian, lung, and liver cancers, and can induce cancer cell apoptosis, for example, in liver
cancer cell lines, including but not limited to HepG2, SK-Hep-1, Hep3B, SUN449, and Huh7 cells,
with low cytotoxic effects on normal cells [11–16].
Despite curcumin’s beneficial effects, its low oral bioavailability (due to its low absorption
in the gut because of low solubility in water, fast metabolism by the liver, and rapid systemic
elimination) has limited its applications [17–19]. Various methods have been developed to improve
the oral bioavailability of curcumin, such as the use of a natural enhancer, a curcumin-phospholipid
complex, cyclodextrin and microemulsions, and the development of curcumin analogs [20–22]. In this
study, we selected the pellet form, a multiple-unit dosage form, as a vehicle for compound delivery.
Pellets disperse freely in the gastrointestinal tract, so they invariably maximize drug absorption [23].
In addition, to improve the solubility of curcumin, we used a solid dispersion technique to formulate
pellets. In solid dispersions, the particle size of poorly soluble drugs is reduced and their wettability
and dispersibility enhanced, thereby improving their dissolution and absorption rate [24].
The Connectivity Map (C-Map) is a systematic database that establishes the relationship between
diseases, genes, and compounds [25]. Recently, the database has been expanded and renamed C-Map
and Library of Integrated Network-Based Cellular Signatures (LINCS) Unified Environment (CLUE)
(https://clue.io/) [26]. Briefly, C-Map and CLUE use gene expression profiles to describe the biological
states of cultured human cancer or normal cells to determine their chemical or genetic constructs
(short hairpin RNA [shRNA] constructs). The new, low-cost, high-throughput generic solution for
gene expression profiles is termed “L1000.” CLUE not only expands the 1309 compounds listed in
C-Map to 19,811 small molecules but also includes 5075 shRNA and overexpression genes. In addition,
users find CLUE relatively convenient to quickly search for a drug class with a similar mechanism
of action (MOA) as a target drug or the same gene family of genetic perturbagens, they codify the
class-level annotation required considerable effort, perturbagen classes (PCLs). For example, users can
compare their target, such as a disease gene signature or a novel compound, with C-Map and CLUE
through pattern-matching algorithms and predict dissimilarities (search for a drug to reverse a disease)
or similarities (search for a similar MOA via known compounds). They could upload gene expression
profiles to C-Map and CLUE to calculate the connectivity score of each profile. A positive connectivity
score would indicate a degree of similar mechanism, while a negative connectivity score would denote
the reverse.
HCC is the fifth-most common malignancy worldwide. More than 75% of HCC cases occur in
the Asia-Pacific region. The high mortality rate because of HCC is due to the difficulty in diagnosis
and poor prognosis. Chemotherapy is a traditional choice for inoperable HCC, but drug resistance
limits the therapeutic effect [27,28]. Sorafenib is a multi-kinase inhibitor that targets Raf kinases as
well as vascular endothelial growth factor receptor (VEGFR)-2/VEGFR-3, platelet-derived growth
factor receptor beta (PDGFR-β), Flt-3, and c-Kit. Because of its potential in providing a survival
advantage of two to three months, as per results of two-phase III clinical studies, sorafenib is a Food
and Drug Administration (FDA)-approved, first-line targeted therapy agent for treating advanced
HCC patients [29,30]. However, the low tumor response rate and side effects of sorafenib indicate the
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need for investigating other new potential drugs or supplementary foods for HCC [31,32]. In this
study, we investigated the anticancer activity of conventional and formulated curcumin and their
combination with sorafenib in order to determine whether this combination can induce HCC cell
apoptosis and autophagy and inhibit HCC cell proliferation. Formulated curcumin can be used as
a functional food and alternative medicine in cancer therapy as it not only causes mitotic defects and
cell cycle arrest in cancer cells but also alters chemosensitivity toward anticancer drugs by inducing
Aurora-A suppression.
2. Materials and Methods
2.1. Materials and Methods Used in Manufacturing Formulated Curcumin
2.1.1. Preparation of Curcumin Solid Dispersion Loaded Pellet
A curcumin standard with a purity > 95.6% was purchased from Sigma-Aldrich.
We used a solid dispersion technique to enhance the solubility and dissolution rate of curcumin [24].
Briefly, the process of making formulated curcumin included dispersing curcumin powder into a solid
dispersion solution and spraying it onto sugar spheres. Tumeric extract powder contained 95%
curcumin in 80 g (as the active drug). The excipients used in the preparation process of solid dispersion
curcumin were Polyvinylpyrrolidone #k30 800 g (PVP K30, as the non-volatile polymer solvent for
curcumin) and alcohol 3200 g (as the volatile solvent for curcumin). The turmeric extract powder was
mixed with the excipients. The drug-polymer interaction evenly dispersed curcumin in the solvent.
Next, the solvent containing solid dispersion curcumin was loaded onto sugar spheres by spray-drying
to make solid dispersion pellets; the solvent evaporated during fluid-bed granulation (Figure 1).
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Figure 1. Preparation of solid dispersion curcumin. Turmeric extract powder, containing 80 g of
95% curcumin (as the active drug), was mixed with excipients (800 g PVP as the nonvolatile polymer
solvent in the presence of alcohol as the volatile solvent for curcumin). The drug-polymer interaction
evenly dispersed curcumin in the solvent. Then, the solvent containing solid dispersion curcumin
was loaded onto sugar spheres by fluid-bed granulation to make solid dispersion curcumin pellets.
PVP, polyvinylpyrrolidone.
2.1.2. Measurements of Particle Size and Zeta Potential
Particle size (Z-average, nm), polydispersity index (PDI), and ζ-potential (ZP, mV) of curcumin
particles after re-dispersion in water were determined at 25 ◦C by dynamic light scattering (DLS) using
a Zetasizer Nano ZS90 (Malvern Instruments, Malvern, UK). Measurements were performed with
a detector at a fixed angle of 90◦, in triplicate, and results were shown as mean ± SD. About 60 mg
Nutrients 2019, 11, 2982 4 of 22
of pellets were dispersed into 2 mL water and centrifuged at 2000 × g for 1 minute to remove starch
particles originated from sugar spheres. Supernatant was aspirated to measure size and ZP.
2.1.3. Dissolution Test
A dissolution test was conducted by the US Pharmacopeia 41 basket method (apparatus 1) using
a dissolution tester (708-DS Dissolution apparatus, Agilent, USA). The samples of 89 mg conventional
curcumin (equivalent to 72 mg curcumin) and 2180 mg formulated curcumin (equivalent to 72 mg
curcumin) were placed into 900 mL of dissolution medium containing 1% sodium dodecyl sulfate
(SDS) at 37 ◦C ± 0.5 ◦C, under a stirring speed of 100 ± 2 rpm. A 5 mL sample was withdrawn at each
time interval (5, 10, 15, 20, 30, 45, and 60 minutes) and was mixed and filtered through a 0.45-µm pore
membrane. Then, 2 mL of filtrate was diluted with mobile phase so that the total volume became
10 mL and subjected to HPLC analysis (Agilent 1260, USA). The HPLC program consisted of a mobile
phase of tetrahydrofuran: 0.1% citric acid solution (4:6). The column used was 4.6 mm × 20 cm with
5-µm packing L1. The flow rate was 1 mL/minute, and the injection volume was 20 µL using a 420 nm
wavelength detector. The percentages of curcumin dissolved from the conventional curcumin and
pellets (formulated curcumin) into the medium were calculated and compared.
2.2. Pharmacokinetic Study
2.2.1. Animal Model
All animal treatment procedures followed the Guide for the Care and Use of Laboratory Animals
(National Institutes of Health (NIH) publication, 85–23, revised 1996) as well as the Animal research:
Reporting in vivo experiments (ARRIVE) guidelines, and were approved by the Animal Research
Committee at National Yang-Ming University, Taipei, Taiwan, under Institutional Animal Care and
Use Committees (IACUC) approval no: 990103. All surgeries and experimental procedure were carried
out under anesthesia with all efforts to minimize animal suffering.
Twelve male Sprague Dawley (SD) rats (270 ± 15 g body weight) were obtained from Bio-Lasco,
Taipei, Taiwan. Water was provided ad libitum, regardless of administration route. All animals were
acclimatized and quarantined in quarantine room of the Rosetta animal facility for about 1 week,
and then transferred to feeding room. The humidity and temperature were well controlled as 30%–70%
and 19–25 ◦C. The light and dark cycle was set as 12 h: 12 h. Food and drinking water were allowed ad
libitum during housing.
Rats were randomly divided into two groups treated with curcumin and formulated curcumin.
Curcumin (conventional; 500 mg/kg, n = 6) and 500 mg/kg formulated curcumin (equal to curcumin
60 mg/kg, n = 6) were administrated by gavage to the freely moving rats, respectively. A 300 µL blood
sample was collected from the tail vein into a tube rinsed with heparin at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6 h
after oral administration.
2.2.2. Sample Pretreatment
Plasma was obtained by centrifuging the blood sample at 4000 rpm for 10 minutes at 4 ◦C.
The 10 µL plasma was mixed with 50 µL of the internal standard solution containing 0.1 ng/µL of
agomelatine. The samples were vortexed and centrifuged at 13,000 rpm for 5 minutes. The 50 µL of
supernatant was transferred to the 1.5 mL tube contained 50 µL solution of 25% acetonitrile and 0.1%
acetic acid. After that, 50 µL of the solution was injected onto LC-MS system.
2.2.3. LC/MS/MS Conditions and Data Analysis
Curcumin concentrations in the samples were determined by positive ion electrospray tandem
mass spectrometry using multiple reaction monitoring (MRM). Separation of curcumin was conducted
on a Cosmosil column (5C18-MS-IIPacked column, 120 Å, 5 µm, 4.6 mm I.D. x 150 mm; NACALAI
TESQUE, Inc., Japan) with a mobile phase of acetonitrile-water-formic acid. MS/MS conditions
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consisted of a declustering potential of 50 V, desolvation temperature of 550 ◦C, spray needle of 5500 V,
and collision energy of 30 V.
Pharmacokinetic analysis was calculated using a non-compartmental model with the Phoenix
WinNonlin®(Version 8.0) software. The area under the drug concentration-time curve (AUC) was
used to measure the total amount of curcumin reaching the systemic circulation. The relative oral
bioavailability (BA) of curcumin was calculated according to the following equation: BA (%) = 100
× [(AUCformulated curcumin/doseformulated curcumin]/[(AUCcurcumin/dosecurcumin)]. The pharmacokinetic
results were represented as the mean ± SD. Statistical analysis was performed by t test (SPSS version
10.0) to compare the differences between groups. The level of significance was set at p < 0.05.
2.3. Cell Lines and Cell Culture
The Huh7 and PLC5 cell lines were obtained from National Taiwan University Hospital, Taiwan.
The Mahlavu cell lines were provided by Dr. Muh-Hwa Yang (Institute of Clinical Medicine, National
Yang-Ming University, Taiwan). Hep3B cells were obtained from American Type Culture Collection
(ATCC), Rockville, MD, USA.
HCC cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO)
supplemented with 10% (v/v) fetal bovine serum (FBS, GIBCO), non-essential amino acids (NEAA,
GIBCO), L-glutamine (GlutaMAX™-I Supplement, GIBCO) and 10% penicillin-streptomycin (GIBCO).
These cells were maintained in a humidified incubator with 5% CO2 at 37 ◦C and were regularly
subcultured every 2–3 days.
2.4. Drug Preparation and Cell Exposure
The conventional curcumin was prepared as a 30 mM stock solution in dimethyl sulfoxide (DMSO;
Sigma) and stored at -20 ◦C. Final curcumin concentrations of 1–90 µM were obtained by dilution in
culture medium so that the final concentration of DMSO was less than 1%. Controls contained 0.1%
DMSO in all experiments.
The formulated curcumin was prepared as a 30 mM stock solution (based on the weight of
curcumin) in double distilled water and stored at -20 ◦C. The formulated curcumin was diluted with
cell culture medium to obtain the concentration indicated.
2.5. Proliferation and Viability Assays
Cells were seeded into a 96-well plate (1500–2000 cells/well) overnight and then treated with
curcumin and the formulated curcumin respectively for 0, 24, 48, 72, 96 and 120 h. After treatment,
0.5 µg/mL 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was added to each well
and cultured for 2 h at 37 ◦C. After incubation, the media were removed from the wells. The formazan
crystals formed were then solubilized in DMSO at room temperature for 10 minutes, and then the
absorbance was measured in a multimode microplate reader at 570 nm.
2.6. Mitochondrial Membrane Potential Assay
We employed 5, 5’, 6, 6’-tetrachloro-l, 1’, 3, 3’-tetraethylbenzimidazolcarbocyanine iodide (JC-1),
which was obtained from Cayman Chemical Co., to analyze the mitochondrial membrane potential.
The cells were seeded in 96-well black plates at a density of 7000 cells/well and cultured overnight.
After treatment, JC-1 staining solution was added to each well and incubated at 37 ◦C for 15–30 minutes
in the dark. The plates were obtained by centrifuged at 400 × g at room temperature for 5 minutes,
and the supernatant was discarded. Then, JC-1 assay buffer was added to each well, followed by
centrifugation at 400 × g at room temperature for 5 minutes, after which the supernatant was discarded.
Finally, JC-1 assay buffer was added again to each well for fluorescent analysis using a fluorescent
plate reader.
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2.7. Annexin V and Propidium Iodide (PI) Double Staining by Flow Cytometry
The Huh7 were incubated with various concentrations of conventional and formulated curcumin
for 24 h. Annexin V/PI staining was performed to quantify cell apoptosis using an Annexin V-fluorescein
isothiocyanate (FITC) Apoptosis Detection Kit (BioVision, Inc., Milpitas, CA, USA) according to the
manufacturer’s protocol. Annexin V-FITC was then added followed by incubation for 15 minutes in
the dark in a 100 µL cell suspension. PI was then spiked into 400 µL Annexin V binding buffer and
added immediately to the cell suspension, and subsequently analyzed on a FACScan flow cytometer
(BD Biosciences, USA).
2.8. Western Blot
The cells were incubated with various treatment (conventional and formulated curcumin
or combination of sorafenib and conventional and formulated curcumin), and then collected
for western blot. Aliquots of cell lysates containing 20–50 µg of protein were separated by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto a polyvinylidene difluoride
(PVDF) membrane and detected using specific primary and secondary antibodies. The protein bands
were visualized by an enhanced chemiluminescence (ECL) detection kit (ImmobilonTM western,
Millipore). The membranes were reprobed for β-actin as a loading control. All western blots were
carried out at least three times for each experiment. The data were normalized to β-actin. The following
primary antibodies were used: anti-extracellular regulated protein kinases (ERK), anti-caspase-3,
anti-poly (ADP-ribose) polymerase (PARP) (all from Cell Signaling Technology) and anti-aurora kinase
A (AURKA) (BD Biosciences). All antibodies were used at a 1:1000 dilution.
2.9. Cell Cycle Analysis
After treatment, the cells were collected by trypsinization and fixed in precooled 70% ethanol
overnight. The cells were then incubated with PI in the presence of RNase A. The DNA content was
analyzed by a FACSCalibur, and the data were analyzed by Flowjo software. The percentage of cells in
the sub-G1 was used to indicate the apoptosis rate.
2.10. Analysis the Similar Mechanism of Gene Expression Profiles of Conventional and Formulated Curcumin
Using the L1000 Microarray
Human HCC (HepG2) and human colorectal cancer (HT29) cell lines (ATCC) were treated in
triplicate with 20µM of conventional curcumin or 2µM of formulated curcumin. Briefly, for experiments
using formulated curcumin, 2 µM of curcumin formulation and curcumin excipient were dissolved in
DMSO and incubated with HepG2 and HT29 cell lines. The samples were submitted to Genometry,
Inc. (Cambridge, MA, USA) for L1000 microarray analysis and to obtain the gene expression profiles
of formulated curcumin in HepG2 and HT29. Each set of gene expression profiles consisted of up-
and down-regulated gene signatures. Subsequently, CLUE was used to decipher the gene signatures
in order to uncover potential mechanisms via mapping to compounds with known MOAs. To filter
output data, we used a score > 90 for compounds and a score > 70 for PCLs.
2.11. Statistical Analysis
All values were expressed as the mean ± SD. The data were analyzed using a two-tailed student’s
t test. A p < 0.05 was considered as statistically significant.
3. Result
3.1. Preparation and Evaluation Formulated Curcumin
First, we prepared the formulated curcumin from powder to pellets with a solid dispersion
technique as described in detail in the Materials and Methods section. The pellet size of formulated
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curcumin estimated by sieving was distributed in the range of 830–1000 µm. Curcumin content
quantified by HPLC was 3.3%. Z-average (nm), PDI, and ZP (mV) of curcumin particles after
re-dispersion in water were 141.9 ± 5.1, 0.308 ± 0.029 and −2.49 ± 0.39, respectively (Table 1).
The dissolution rates of conventional curcumin were 0.00%, 9.80%, 13.60%, 14.05%, 17.28%, 19.41%,
24.06%, and 26.28%, while those of the formulated curcumin were 0.00%, 59.03%, 87.50%, 98.78%,
100.22%, 101.20%, 102.29%, and 103.65% at 0, 5, 10, 15, 20, 30, 45, and 60 minutes, respectively
(Supplementary Figure S1). In the 1% SDS medium, more than 85% of curcumin was almost immediately
released from the pellets after 10 minutes. Additionally, when compared to the US Pharmacopeia
specifications for dissolution of curcuminoid capsules or curcuminoid tablets, the dissolution of the
formulated curcumin was not lower than 75% after 60 minutes, suggesting that the formulation greatly
increased curcumin’s solubility.
Table 1. Properties of formulated curcumin.
Properties of Formulated Curcumin Value
Pellet size (µm) 830–1000
Curcumin level (%) 3.3
Z-average (nm) 141.9 ± 5.1
Polydispersity index (PDI) 0.308 ± 0.029
Zeta potential (mV) –2.49 ± 0.39
3.2. Oral Administration of Formulated Curcumin Shows an Increase in Bioavailability over Conventional
Curcumin via Pharmacokinetic Analysis
To determine the actual amount of curcumin that was released and existed in the formulated
curcumin, a high-performance liquid chromatography assay and LC-MS method was adopted for
the quantification of curcumin. To investigate whether the bioavailability of curcumin was increased
after formulation, 60 mg/kg of formulated curcumin was orally administered in a rat model and
the plasma samples were subjected to chromatography. To confirm the reliability of the method for
analyzing curcumin in plasma samples, a method validation was performed. The retention times of
curcumin were about 5.14 minutes, with no visible interference peak in the blank plasma chromatogram
(data not shown). To perform a pharmacokinetic analysis, the curcumin concentrations in rat plasma
at different time points following oral administration of 500 mg/kg of curcumin and 60 mg/kg of
formulated curcumin were compared (Figure 2). However, administration of 500 mg/kg of curcumin
had very low amount of curcumin in rat plasma and resulted to a huge increase of bioavailability.
Therefore, the pharmacokinetic parameters of curcumin represented an estimated number and will be
compared with others from literatures (see later in discussion). AUC represents the total drug exposure
over time. Based on the pharmacokinetic parameters (Table 2), the AUC represents the total drug
exposure over time. The AUC normalized by dose of curcumin was increased from 0.0021 to 1.864,
which is an 887.6-fold increase after formulation. Overall, this result showed that oral administration
of formulated curcumin significantly increased the oral bioavailability of curcumin compared with
conventional curcumin.
3.3. Gene Expression Analysis of Formulated Curcumin and Prediction of Highly Correlated Pathways
We queried CLUE with regard to the analyzed group of genes in order to identify potential
biological functions of formulated curcumin. The top 30 compounds (Figure 3C) and PCLs (Figure 3A)
with the highest scores were obtained from CLUE. Intersection of results from both cell lines revealed that
seven compounds (e.g., menadione and angiogenesis inhibitor; Figure 3D) and two PCLs (e.g., NF-κB
pathway inhibitors; Figure 3B) shared common functions with conventional curcumin. In summary,
formulated curcumin was similar to conventional curcumin, and both functioned as, for example, NF-κB
pathway inhibitors, which is consistent with previous studies [33]. We intersected two sample groups
to identify common PCL/compound classes between formulated curcumin treatment of HT29 cells and
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formulated curcumin treatment of HepG2 cells. Consequently, we identified two PCLs (including NF-κB
pathway inhibitors and vesicular transport loss of function (LOF; Figure 3B), and seven compounds
belonging to the NF-κB pathway inhibitor PCL class were common among all groups.
In fact, CLUE revealed that only the MOA of compounds or shRNAs was similar to that of
formulated curcumin; CLUE did not indicate the target of formulated curcumin. Therefore, to obtain
more information about formulated curcumin, we used another database for assistance pathway
analysis, ConsensusPathDB (CPDB). CPDB comprises interactions among different types of various
intracellular information, such as genes, RNA, proteins, and metabolites, to predict a relatively
comprehensive and unbiased cellular biology signal result. We used the Venny website to intersect our
two sets of PCL results (Figure 3B) and selected their targets and members genes to predict potential
pathways of formulated curcumin (Figure 4). According to q < 0.001, we listed the top 20 pathways at
the bottom of Figure 4, and the details are in Supplementary Figure S2. In addition, we showed similar
effects in L1000 microarray profiles between conventional and formulated curcumin in heatmaps
(Figure 5). These data suggested that formulated curcumin exhibits similar biological functions as
conventional curcumin.
Table 2. Pharmacokinetic parameters of curcumin in rat plasma following oral administration.
Parameters
Oral
Conventional Curcumin* (n = 5) Formulated Curcumin (n = 6)
500 mg/kg 60 mg/kg
Cmax (ng/mL) 0.704 ± 0.272 109.200 ± 41.651
AUC0-t (h × ng/mL) 1.1 ± 1.2 111.8 ± 16.4
AUC0-t/Dose 0.0022 ± 0.0024 1.863 ± 0.273
Tmax(h) 1.25 ± 0.83 0.38 ± 0.14
The data are expressed as the mean ± SD. Cmax: the maximum plasma concentration; Tmax: the time at which
Cmax is observed; AUC0-t: area under the concentration-time curve from the time of drug administration to the last
quantifiable concentration. *: Conventional curcumin in some rat plasma samples was very low and was assigned to
0 for calculations. We were unable to detect curcumin from the plasma of one rat during the experimental periods,
and thus data from five rats were used for calculations.
Nutrients 2019, 11, x FOR PEER REVIEW 8 of 23 
The data are expressed as the mean ± SD. Cmax: the maximum plasma concentration; Tmax: the time at 
which Cmax is observed; AUC0-t: area under the concentration-time curve from the time of drug 
administration to the last quantifiable concentration. *: Conventional curcumin in some rat plasma 
sampl s was very low an  was assig ed t  0 for calculations. We were unable to detect curcumin 
from the plasma of one rat during the experimental periods, and thus data from five rats were used 
for calculations. 
 
Figure 2. Mean plasma concentration-time profiles of curcumin in male SD rats following 500 mg/kg 
conventional curcumin (A) and 60 mg/ kg formulated curcumin (B) after single dose oral gavage 
(P.O.) linear ordinate. The data are expressed as mean ± SD, n = 5 for curcumin and n = 6 for 
formulated curcumin. 
3.3. Gene expression analysis of formulated curcumin and prediction of highly correlated pathways 
We queried CLUE with regard to the analyzed group of genes in order to identify potential 
biological functions of formulated curcumin. The top 30 compounds (Figure 3C) and PCLs (Figure 
3A) with the highest scores were obtained from CLUE. Intersection of results from both cell lines 
revealed that seven compounds (e.g., menadione and angiogenesis inhibitor; Figure 3D) and two 
PCLs (e.g., NF-κB pathway inhibitors; Figure 3B) shared common functions with conventional 
curcumin. In summary, formulated curcumin was similar to conventional curcumin, and both 
functioned as, for example, NF-κB pathway inhibitors, which is consistent with previous studies 
[33]. We intersected two sample groups to identify common PCL/compound classes between 
formulated curcumin treatment of HT29 cells and formulated curcumin treatment of HepG2 cells. 
Consequently, we identified two PCLs (including NF-κB pathway inhibitors and vesicular transport 
loss of function (LOF; Figure 3B), and seven compounds belonging to the NF-κB pathway inhibitor 
PCL class were common among all groups. 
In fact, CLUE revealed that only the MOA of compounds or shRNAs was similar to that of 
formulated curcumin; CLUE did not indicate the target of formulated curcumin. Therefore, to obtain 
more information about formulated curcumin, we used another database for assistance pathway 
analysis, ConsensusPathDB (CPDB). CPDB comprises interactions among different types of various 
intracellular information, such as genes, RNA, proteins, and metabolites, to predict a relatively 
comprehensive and unbiased cellular biology signal result. We used the Venny website to intersect 
our two sets of PCL results (Figure 3B) and selected their targets and members genes to predict 
potential pathways of formulated curcumin (Figure 4). According to q < 0.001, we listed the top 20 
pathways at the bottom of Figure 4, and the details are in Supplementary Figure S2. In addition, we 
showed similar effects in L1000 microarray profiles between conventional and formulated curcumin 
in heatmaps (Figure 5). These data suggested that formulated curcumin exhibits similar biological 
functions as conventional curcumin. 
Figure 2. Mean plasma concentration-time profiles of curcumin in male SD rats following 500 mg/kg
conventional curcumin (A) and 60 mg/ kg formulated curcumin (B) after single dose oral gavage
(P.O.) linear ordinate. The data are expressed as mean ± SD, n = 5 for curcumin and n = 6 for
formulated curcumin.
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Figure 3. Gene analysis data of formulated curcumin. (A) The L1000 gene expression profiles of HT29
and HepG2 cells treated with formulated curcumin were analyzed by CLUE. The output data of PCLs
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in both HT29 and HepG2 are shown at the bottom (score > 70). (B) PCLs list a score > 70 and are
intersected by Venny website. Two common PLCs, NF-κB pathway inhibitor and vesicular transport
LOF, are shown in the diagram. To avoid missing possible predicted functions of formulated curcumin,
we used an intersection-driven approach to broadly cover these PCLs (score > 70). (C) The top
30 compounds (CP) are representative, while the complete list is provided in the Supplementary
Information (score > 90). Details are in Supplementary Figure S3. (D) Intersection compounds
using L1000 array analysis of formulated curcumin by CLUE. The connectivity score is based on the
Kolmogorov–Smirnov enrichment statistical evaluation of each gene expression profile. The results
provided from CLUE are expressed as a comprehensive connectivity score, showing that the same
drug has a similar MOA on different cancer cells in CLUE, Connectivity Map and Library of Integrated
Network-Based Cellular Signatures (LINCS) unified environment; PCL, perturbagen class; MOA,
mechanism of action.
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The Venn diagram shows the intersecting PCLs (top, right). We focused on intersection results indicated
by red circles. The results contained two PCLs, NF-κB pathway inhibitors and vesicular transport
LOF and used their targets and member gene lists (total 22 genes) to query CPDB in order to analyze
interaction network modules, biochemical pathways, and functional information. Top 50 prediction
pathways are listed in Supplementary Figure S2, and top 20 pathways identified by CPDB analysis
(q < 0.001) are shown at the bottom of the figure. The size of each dot denotes the entity number of
genes in the pathway. The line between two dots was calculated by the function of these two pathways
to indicate the number of genes overlapping said pathways. The breadth of the line denotes the
strength of the correlation between two dots. The apoptosis was analyzed in this study (highlighted
in yellow, Supplementary Figure S2). CPDB, ConsensusPathDB; PCL, perturbagen class; shRNA,
short hairpin RNA.
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3.4. Formulated Curcumin Displays Stronger Inhibition on Population Growth of Huh7 Cells
To determine whether formulated curcumin retains the biological functions of conventional
curcumin, we performed MTT assay to assess the cell proliferation and cell viability of conventional
curcu in and formulated curcumin-treated Huh7 cells. As shown in Supplementary Figure S4,
when the concentration of conventional or formulated curcumin increased, cell viability decreased
after treatment with curcumin for 24–120 h. We also observed cytotoxicity of curcumin in Huh7 cells.
The 50% inhibitory concentration (IC50) value for conventional curcumin at 24, 48, 72, 96, and 120 h
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was around 90, 90, 60, 45, and 30 µM, respectively, while the IC50 value for formulated curcumin was
around 60, 60, 30, 10, and 10 µM, respectively.
3.5. Cytotoxic Effect of Curcumin on Other HCC Cell Lines
To determine whether conventional and formulated curcumin could mediate the survival of
other HCC cell lines, we first examined the effect of conventional and formulated curcumin on the
viability of Huh7, Mahlavu, and PLC5 cells using MTT assay. While Huh7 cells are well differentiated,
Mahlavu and PLC5 cells are poorly differentiated and carry p53 mutations. To explore the cytotoxic
activity of conventional and formulated curcumin against these HCC cell lines, we initiated an in vitro
study by treating Huh7, Mahlavu, and PLC5 cells each with increasing dosages of conventional
and formulated curcumin (0, 1, 3, 10, 30, 60, and 90 µM) for 72 h. MTT assay results indicated that
both conventional and formulated curcumin significantly inhibit the viability of Huh7 (Figure 6A),
Mahlavu (Figure 6B), and PLC5 (Figure 6C) cells. After 72 h post-treatment, formulated curcumin
caused cytotoxicity in Huh7, Mahlavu, and PLC5 cells with an IC50 value of 38.1, 10.1, and 60.9 µM,
respectively, while the IC50 values of conventional curcumin were 53.3, 35.4, and 82.5 µM, respectively
(Figure 6A–C). Taken together, the results showed that both conventional and formulated curcumin
inhibited the survival and proliferation of HCC cell lines in a dose-dependent manner. In addition,
formulated curcumin was more effective than conventional curcumin.
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Mahlavu, and PLC5). After separate treatment ith 1, 3, 10, 30, 60, and 90 µM of conventional and
formulated curcumin for 72 h, cell viability was determined by MTT assay and expressed as a percentage
relative to the control group. Formulated curcumin was more effective than conventional curcumin on
the basis of cell viability in the three cell lines tested. Formulated curcumin has higher cytotoxicity
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tetrazolium bromide.
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3.6. Effects of Curcumin on Apoptosis-Related Protein Expression
MTT assay indicated that both conventional and formulated curcumin suppress cell viability.
To determine whether cell viability inhibition is due to apoptosis, we examined the degree of apoptosis
by PI and annexin V staining using flow cytometry. The results clearly demonstrated that 24 h
post-treatment with 10–60 µM of conventional and formulated curcumin, the percentage of cells
undergoing early apoptosis (annexin V+/PI–) and late apoptosis (annexin V+/PI+) increased, while the
percentage of viable cells decreased (annexin V–/PI–) in a dose-dependent manner (Figure 7A).
Comparison of effectiveness between conventional and formulated curcumin showed no significant
statistical difference.
Caspase-3 activation is crucial for mitochondrial-dependent and mitochondrial-independent
apoptotic pathways. Therefore, we examined the activity of caspase-3 by observing its active form
(cleaved form) by western blotting in Huh7 cells (Figure 7B). Both conventional and formulated
curcumin increased caspase-3 activity in Huh7 cells in a dose-dependent manner (Figure 7B). Caspase-3
activation led to cleavage of several substrates, including PARP. PARP cleavage was also determined
by western blotting (Figure 7B). Therefore, conventional and formulated curcumin separately induced
apoptosis by activating caspase-3 (Figure 7B).
Many antineoplastic drugs induce apoptosis of cancer cells via mitochondrial apoptotic
pathways [34–36]. A hallmark of apoptosis induction via these pathways is a rapid, early breakdown
of the mitochondrial membrane potential. Therefore, in this study, we also analyzed the mitochondrial
function integrity posttreatment with conventional and formulated curcumin. Both conventional and
formulated curcumin significantly induced mitochondrial membrane potential breakdown (∆Ψm) in
a concentration-dependent manner (Figure 7C), as determined by ELISA using the potential-sensitive
dye JC-1.
Previous studies have shown that curcumin inhibits cancer cell proliferation via suppression of
the ERK signaling pathway [37–39]. To investigate whether the ERK signaling pathway is involved
in curcumin-induced apoptosis, ERK activation was evaluated by detecting ERK phosphorylation.
Huh7 cells were exposed to 10–60 µM of conventional curcumin and formulated curcumin separately
for 48 h, and ERK activation was determined by western blotting. As shown in Figure 7D, both
conventional and formulated curcumin-induced phosphor-ERK down-regulation but with little change
in the total ERK protein in Huh7 cells.
Recent studies have suggested that a curcumin-induced mitotic spindle defect and cell cycle
arrest in human cancer cells occur through Aurora kinase inhibition [40–42]. To determine whether
conventional and formulated curcumin inhibit Huh7 cell proliferation via down-regulation of Aurora-A
expression, Huh7 cells were incubated with 0–60 µM of conventional and formulated curcumin
separately for 48 h. We observed a significant decrease in the level of Aurora-A by western blotting
(Figure 7D). These data suggested that the biological function of both conventional and formulated
curcumin involves caspase-3 activation and ERK and Aurora-A down-regulation.
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3.7. Effects of Combination of Curcumin and Sorafenib
Sorafenib and curcumin both inhibited cell viability of two HCC cell lines (Huh7 and Hep3B) in
a dose-dependent manner (Supplementary Figures S5 and S6). Therefore, we explored the potential
effects of sorafenib in combination with conventional or formulated curcumin on Huh7, Mahlavu,
and Hep3B cell proliferation. The cells were treated with various concentrations of sorafenib in
combination with conventional or formulated curcumin for 48 h (Supplementary Figures S5A and S6).
The results indicated that the combination of conventional or formulated curcumin with sorafenib has
a stronger inhibitory effect on the population growth of HCC cell lines.
In this study, we demonstrated that both conventional and formulated curcumin inhibit Aurora
kinase, preferentially suppress proliferation, and induce apoptosis of HCC cell lines. A previous
study also indicated that curcumin induces apoptosis-associated autophagy [43,44]. Therefore,
we investigated whether the combination of sorafenib and conventional or formulated curcumin can
increase apoptosis of HCC cell lines. Cell cycle analysis revealed that adding conventional curcumin
for 48 h leads to an apoptosis rate of 13.5% (sub-G1 population), similar to the 10.9% rate induced by
sorafenib. We further examined whether conventional curcumin induces apoptosis of Hep3B cells.
We found that the levels of cleaved caspase-3 proteins increased in conventional curcumin-treated,
sorafenib-treated, and combination-treated cells (Supplementary Figure S5C). There was no notable
difference between the three groups. Conventional curcumin and its combination with sorafenib both
significantly induced accumulation of LC3-II (Supplementary Figure S5D), a lipidated form of LC3 that
is considered an autophagosomal marker in mammals. Similar results were found with formulated
curcumin treatment (data not shown). These results suggested that the combination of conventional
curcumin and formulated curcumin separately with sorafenib induces apoptosis-associated autophagy
in HCC cell lines.
4. Discussion
In this study, we reported that (i) both conventional and formulated curcumin induce apoptosis
of HCC cell lines and down-regulate Aurora-A and (ii) a combination of conventional or formulated
curcumin with sorafenib has a stronger inhibitory effect on HCC cell viability, demonstrating a possible
prevention and therapeutic application for formulated curcumin to be used as a food supplement and
medical food.
HCC most often develops and progresses with a lot of oxidative stress and inflammation.
Phytochemicals, such as dietary polyphenols, endowed with potent antioxidant and anti-inflammatory
properties, provide a suitable alternative for alleviation of HCC. Previous studies have reported that
systemic bioavailability of curcumin in humans is very poor [45,46]. Solid dispersion manufacturing
of poorly soluble drugs by spray-drying is a practical commercialization strategy to improve solubility
and dissolution rates because of the reasonable cost of required materials and ease of scale-up [47].
Several methods have been developed to solve issue of low oral bioavailability of curcumin.
One method is the use of a natural enhancer, such as alkaloid piperine. When 20 mg of piperine was
given concomitantly with 2 g of curcumin, the serum curcumin increased by 20 times in humans
and 1.56 times in rats. However, because piperine is a relatively selective CYP3A inhibitor [14],
drug and food interactions with piperine are a concern. Some studies have used phospholipids as
a delivery vehicle for curcumin. The oral bioavailability of curcumin-silica-coated flexible liposomes
(curcumin-SLs) and curcumin-flexible liposomes (curcumin-FLs) was found to be 7.76- and 2.35-fold
higher, respectively, compared to curcumin suspensions [20]. However, large-scale manufacturing will
incur a substantial cost.
In the pharmaceutical industry, solid dispersion pellets are one of the drug delivery solutions
for poorly soluble drugs. Solid dispersion pellets increase the solubility and release rate of a drug.
For example, itraconazole is a triazole antifungal agent with low solubility. In some itraconazole
solid dispersion pellets, the formulated itraconazole showed around 30- and 70-fold increase in the
dissolution rate compared to pure drug [48]. Tanshinone IIA (TA), one of the liposoluble bioactive
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constituents extracted from the root of Salvia miltiorrhiza Bunge, has positive cardiovascular functions
such as vasorelaxation and cardioprotective effects. The oral bioavailability of TA tSD pellets (a solid
dispersion of a combination of PVP and poloxamer 188) in rabbit increased by 5.4 times compared
to TA [49]. In this study, the oral bioavailability of formulated curcumin (solid dispersion pellets)
increased significantly compared to conventional curcumin. Except for curcumin itself, all the materials
used are inert and safe. In addition, because of the simple manufacturing process, solid dispersion
pellets are also suitable for continuous and large-scale manufacturing, and the formulated curcumin
can be used as a food supplement and medical food.
As mentioned in Section 3.1, 830–1000 µm is the size distribution of the pellets (formulated
curcumin) determined by the sieving method. These pellets were formed by spraying ethanol solution
of curcumin and PVP-K30 onto sugar spheres in a fluid-bed granulator machine. After re-dispersion
in water, they were disintegrated to release free curcumin into the water as nanoparticles. The size
of the curcumin particles (Z-average) measured using Zetasizer Nano ZS90 was determined to be
141.9 ± 5.1 nm, which could be filtered by a 0.45-µm pore filter. The nano size of the curcumin particles
made it possible for them to be dissolved quickly in the dissolution medium. This was compatible
with the data of the dissolution test.
In addition, using 1% SDS solution as the media for the dissolution test is mentioned in the US
Pharmacopeia for curcuminoid tablets or curcuminoid capsules. Therefore, we used SDS in the medium
to evaluate how well our newly formulated curcumin was improved in its dissolution by comparison
with conventional curcumin. The results showed that dissolution of conventional curcumin in 1% SDS
solution was only about 20% after 60 minutes, whereas that of the formulated curcumin was more than
85% after 10 minutes.
Supplementary Table S1 summarizes several studies that have reported techniques for enhancing
curcumin oral bioavailability. While the formulated curcumin increases bioavailability over 800-fold,
only approximately 5–100-fold increases have been achieved by other formulations. To clarify this
difference, we investigated several pharmacokinetic parameters of conventional curcumin from these
studies (supplementary Table S2) ([50–52]). In our study, administration of 500 mg/kg of curcumin
resulted in a very low amount of curcumin in rat plasma: AUC0-t (h × ng/mL) was 1.1, whereas in other
studies the AUC0-t (h × ng/mL) were 8.76, 80, and 60 after doses of 50, 340, and 500 mg/kg, respectively,
were administered. If we used these AUC0-t (h × ng/mL) from un-formulated curcumin to calculate the
AUC for the formulated curcumin, an approximately 8–16-fold increase in bioavailability was obtained.
In short, this study showed that oral administration of a novel solid dispersion of curcumin significantly
increased its oral bioavailability compared with that of conventional curcumin. Although the Cmax
of the formulated curcumin is far below the effective concentrations of our cell culture experiments,
administration of conventional curcumin (200 mg/kg) for days or weeks has been reported to exhibit
significant biological activity against both chemically induced and xenograft hepatocarcinogenesis [53].
Because the formulated curcumin (single administration of 60 mg/kg) significantly increased the oral
bioavailability compared with conventional curcumin (single administration of 500 mg/kg), repeating
administration of the formulated curcumin at a higher dosage for a longer period of time can be
expected to achieve a much higher Cmax, and especially AUC, to display the biological effect of
curcumin observed in vitro. It is noteworthy that the formulated curcumin, as expected, retains similar
characteristics to conventional curcumin at the cellular level.
It is well known that the low oral bioavailability of curcumin is due to its poor solubility,
poor intestinal permeability and extensive metabolism. In another study [52], authors have used
phospholipid to formulate liposome of curcumin in order to enhance intestinal absorption of curcumin.
In the fasted rat model (rats were fasted overnight to avoid interference by food), they proved that
the AUC for liposome of curcumin increased about 5.5-fold compared with that for the conventional
curcumin after administration of 340 mg/kg dose; the AUC 26.7 µg × min/mL is equivalent to 445 h
× ng/mL. In our study, rats had free access to food and water. After administrating 60 mg/kg of the
formulated curcumin, the AUC recorded was approximately 111 h × ng/mL. In addition, AUC/dose
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calculated in our study was higher than that in the previous study. Although we enhanced solubility of
curcumin, we suggest that after administration of our formulation, curcumin was quickly released as
nano particles then dissolved in gastric fluid or tiny oil droplet in food. Therefore, a part of curcumin
was absorbed as free form and the rest was absorbed by pathway of oil absorption supported by bile
salts. This was one of the advantages of the formulated curcumin which can be prepared easily and
scaled up in industry. In future, we will conduct more experiments to verify this conclusion.
Both conventional and formulated curcumin were effective in decreasing proliferation and
viability of HCC cell lines in a dose-dependent manner and induced apoptosis of HCC cell lines via
mitochondria dysfunction in vitro. In the cell culture study, both forms of curcumin were dissolved
completely before experiments, thus the benefits of formulated curcumin with improved solubility
and dissolution rates could not be displayed. The in vitro study was carried out mainly to determine if
the formulated curcumin retained similar characteristics of conventional curcumin at the cellular level.
Mitochondrial hyperpolarization is a prerequisite for curcumin-induced apoptosis, and mitochondrial
DNA (mtDNA) damage might be a probable mechanism for curcumin-induced apoptosis of HepG2
cells and might serve as the initial event triggering a chain of events leading to apoptosis [12]. Aurora
kinases, such as Aurora-A, Aurora-B, and Aurora-C, comprise a family of centrosome-associated
serine/threonine kinases that are overexpressed in various cancers and are potentially correlated with
chemoresistance [54–56]. Curcumin administration [57] or Aurora-A inhibition by short interfering RNA
(siRNA) [58] induces apoptosis. Curcumin has also been shown to down-regulate Notch1, the janus
kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, and multidrug resistance
protein 1 (MDR1) expression and to inhibit histone deacetylase 1 (HDAC1) activity [12,13,42,59,60].
Sorafenib is the only chemotherapeutic drug that has been shown to be effective in prolonging the
survival of HCC patients. However, the low rate of tolerance to sorafenib among HCC patients
limits its use [31,32]. Recent preclinical studies have reported that combining sorafenib with other
chemotherapeutic agents exerts synergistic effects [61,62], which could provide a promising strategy
for the treatment of advanced HCC. In this study, conventional or formulated curcumin in combination
with sorafenib inhibited the proliferation of HCC cell lines and exhibited a stronger inhibitory effect
on HCC cell lines. Taken together, the formulated curcumin appeared to have properties similar to
conventional curcumin, raising the possibility that our formulated curcumin could enhance cytotoxicity
against HCC.
In addition, our bioinformatics screening platform effectively identified the molecular mechanisms
of a phytochemical via gene expression profiles. C-Map can be queried to identify specific gene
signatures from small molecules, including FDA-approved drugs. CLUE is similar to C-Map but
considerably larger, with > 1.1 million L1000 profiles; therefore, similarity scores for compounds
in CLUE can be obtained to identify their molecular actions. Similar results for conventional and
formulated curcumin suggested that only solubility and oral bioavailability have been altered in
formulated curcumin. Curcumin is known to exert strong anti-inflammatory effects by interrupting
NF-κB signaling at multiple levels. Based on CLUE analysis, formulated curcumin can be predicted
to have a similar action as NF-κB pathway inhibitors. Furthermore, analysis via CPDB suggests
that curcumin can be linked to TNF related weak inducer of apoptosis as well as TNF mediated
NF-κB pathway. Therefore, our screening platform not only confirms that the formulated curcumin
has similar mechanism with unformulated curcumin, but it also predicts the novel mechanism of
formulated curcumin, such as suppression of HMGB1 mediated inflammation by THBD (label in red
in Supplementary Figure S2).
In conclusion, our curcumin was formulated in pellet form, which not only improved its oral
bioavailability but also provided high flexibility of use. For example, it would be easy to adjust the
dosage and combine the pellets with other ingredients. In addition, as a functional food and alternative
medicine, it would be suitable for those who cannot swallow tablets or capsules.
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area under curve AUC
aurora kinase A AURKA
bioavailability BA
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Dulbecco’s modified Eagle’s medium DMEM
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extracellular regulated protein kinases ERK
hepatocellular carcinoma HCC
high performance liquid chromatography HPLC
histone deacetylase 1 HDAC1
janus kinase JAK
limit of quantification LOQ
limits of detection LOD
multidrug resistance protein 1 MDR1
platelet-derived growth factor receptor beta PDGFR-β




signal transducer and activator of transcription STAT
sodium dodecyl sulfate SDS
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The Food and Drug Administration FDA
vascular endothelial growth factor receptor VEGFR
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